Silo Pharma, Inc.

NasdaqCM:SILO Stock Report

Market Cap: US$4.3m

Silo Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:SILO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
13 Dec 24BuyUS$2,097Eric WeisblumIndividual2,500US$0.84
22 Nov 24BuyUS$4,625Eric WeisblumIndividual5,000US$0.95
12 Jun 24BuyUS$5,533Eric WeisblumIndividual5,000US$1.11
05 Apr 24BuyUS$1,988Eric WeisblumIndividual1,000US$2.03
01 Apr 24BuyUS$8,713Eric WeisblumIndividual4,508US$1.94

Insider Trading Volume

Insider Buying: SILO insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SILO?
Owner TypeNumber of SharesOwnership Percentage
Institutions110,7932.47%
Individual Insiders192,9324.3%
Hedge Funds227,0065.06%
General Public3,953,72588.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.6%.

Top Shareholders

Top 14 shareholders own 11.83% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
5.06%
Renaissance Technologies LLC
227,006US$217.6k0%no data
4.19%
Eric Weisblum
187,932US$180.2k4.16%no data
0.69%
Geode Capital Management, LLC
30,761US$29.5k90.1%no data
0.57%
Virtu Financial LLC, Asset Management Arm
25,615US$24.6k-38.8%no data
0.36%
The Vanguard Group, Inc.
16,334US$15.7k0%no data
0.32%
Citadel Advisors LLC
14,373US$13.8k0%no data
0.28%
State Street Global Advisors, Inc.
12,500US$12.0k0%no data
0.13%
Fédération des Caisses Desjardins du Québec, Asset Management Arm
6,000US$5.8k0%no data
0.11%
Daniel Ryweck
5,000US$4.8k0%no data
0.091%
Tower Research Capital Europe Limited
4,061US$3.9k-39%no data
0.023%
Lazard Asset Management LLC
1,018US$975.80%no data
0.0021%
Westside Investment Management, LLC
94US$90.30%no data
0.0008%
Bank of America Corporation, Asset Management Arm
36US$34.4112%no data
0.00002%
JPMorgan Chase & Co, Brokerage and Securities Investments
1US$0.90%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:59
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Silo Pharma, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
I-Eh JenLaidlaw & Company (UK) Ltd